File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/0024-3205(95)00005-Q
- Scopus: eid_2-s2.0-0028891681
- PMID: 7885190
- WOS: WOS:A1995QD54300005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Insulin-like growth factor-1 is not mitogenic for the Walker-256 carcinosarcoma
Title | Insulin-like growth factor-1 is not mitogenic for the Walker-256 carcinosarcoma |
---|---|
Authors | |
Keywords | flow cytometry insulin-like growth factor tumor cell-cycle proliferation |
Issue Date | 1995 |
Publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/lifescie |
Citation | Life Sciences, 1995, v. 56 n. 10, p. 747-756 How to Cite? |
Abstract | This study was designed to determine whether intravenous infusion of recombinant human insulin-like growth factor 1 (IGF-1) stimulates tumor growth. In order to determine the potential interaction between nutrition and IGF-1 administration the study was conducted in fasting rats and during continuous feeding by total parenteral nutrition. Tumor cell cycle kinetics including labeling index, DNA synthesis time, cell cycle time in G0/G1, and G2/M in the total cell cycle, and potential doubling time were determined by flow cytometry after in vivo pulse labeling the rats bearing the Walker-256 Carcinosarcoma with 5'-bromo-2'-deoxyuridine (BrdUrd). The results show that IGF-1 treatment has no significant effects on the proliferative characteristics of the tumor model regardless of the feeding status of the animal. This study provides preliminary cell-cycle kinetics data on the short-term effect of IGF-1 on tumor growth. Failure to show a significant effect of IGF-1 on the proliferative characteristics of the tumor suggests that IGF-1 may be given to cancer patients in amounts sufficient to promote weight gain without deleterious stimulation of tumor proliteration. |
Persistent Identifier | http://hdl.handle.net/10722/178572 |
ISSN | 2023 Impact Factor: 5.2 2023 SCImago Journal Rankings: 1.257 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wan, JMF | en_US |
dc.contributor.author | Istfan, NW | en_US |
dc.contributor.author | Ye, SL | en_US |
dc.contributor.author | Bistrian, BR | en_US |
dc.date.accessioned | 2012-12-19T09:48:28Z | - |
dc.date.available | 2012-12-19T09:48:28Z | - |
dc.date.issued | 1995 | en_US |
dc.identifier.citation | Life Sciences, 1995, v. 56 n. 10, p. 747-756 | en_US |
dc.identifier.issn | 0024-3205 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/178572 | - |
dc.description.abstract | This study was designed to determine whether intravenous infusion of recombinant human insulin-like growth factor 1 (IGF-1) stimulates tumor growth. In order to determine the potential interaction between nutrition and IGF-1 administration the study was conducted in fasting rats and during continuous feeding by total parenteral nutrition. Tumor cell cycle kinetics including labeling index, DNA synthesis time, cell cycle time in G0/G1, and G2/M in the total cell cycle, and potential doubling time were determined by flow cytometry after in vivo pulse labeling the rats bearing the Walker-256 Carcinosarcoma with 5'-bromo-2'-deoxyuridine (BrdUrd). The results show that IGF-1 treatment has no significant effects on the proliferative characteristics of the tumor model regardless of the feeding status of the animal. This study provides preliminary cell-cycle kinetics data on the short-term effect of IGF-1 on tumor growth. Failure to show a significant effect of IGF-1 on the proliferative characteristics of the tumor suggests that IGF-1 may be given to cancer patients in amounts sufficient to promote weight gain without deleterious stimulation of tumor proliteration. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/lifescie | en_US |
dc.relation.ispartof | Life Sciences | en_US |
dc.subject | flow cytometry | - |
dc.subject | insulin-like growth factor | - |
dc.subject | tumor cell-cycle proliferation | - |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Bromodeoxyuridine - Metabolism | en_US |
dc.subject.mesh | Carcinoma 256, Walker - Pathology | en_US |
dc.subject.mesh | Cell Cycle | en_US |
dc.subject.mesh | Cell Division | en_US |
dc.subject.mesh | Dna - Biosynthesis | en_US |
dc.subject.mesh | Fasting | en_US |
dc.subject.mesh | Flow Cytometry | en_US |
dc.subject.mesh | Insulin-Like Growth Factor I - Pharmacology | en_US |
dc.subject.mesh | Kinetics | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Parenteral Nutrition, Total | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, Sprague-Dawley | en_US |
dc.subject.mesh | Recombinant Proteins - Pharmacology | en_US |
dc.title | Insulin-like growth factor-1 is not mitogenic for the Walker-256 carcinosarcoma | en_US |
dc.type | Article | en_US |
dc.identifier.email | Wan, JMF: jmfwan@hku.hk | en_US |
dc.identifier.authority | Wan, JMF=rp00798 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/0024-3205(95)00005-Q | en_US |
dc.identifier.pmid | 7885190 | - |
dc.identifier.scopus | eid_2-s2.0-0028891681 | en_US |
dc.identifier.volume | 56 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.spage | 747 | en_US |
dc.identifier.epage | 756 | en_US |
dc.identifier.isi | WOS:A1995QD54300005 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Wan, JMF=8930305000 | en_US |
dc.identifier.scopusauthorid | Istfan, NW=7003819779 | en_US |
dc.identifier.scopusauthorid | Ye, SL=7202088340 | en_US |
dc.identifier.scopusauthorid | Bistrian, BR=35463916700 | en_US |
dc.identifier.issnl | 0024-3205 | - |